Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 13/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | PLD2 | O14939 | 2/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544013 | 0.96 | CCR5 (0.66) | CCR5OPRM1OPRL1PLD2PLD1 | |
| SCHEMBL4740667 | 0.92 | CCR5 (0.80) | CCR5OPRM1OPRL1 | |
| SCHEMBL4685629 | 0.91 | CCR5 (0.64) | CCR5OPRM1OPRL1PLD2PLD1 | |
| SCHEMBL4682434 | 0.90 | CCR5 (0.85) | CCR5OPRM1OPRL1 | |
| SCHEMBL6170250 | 0.90 | CCR5 (0.63) | CCR5OPRM1OPRL1 | |
| SCHEMBL5511844 | 0.89 | CCR5 (0.85) | CCR5 | |
| SCHEMBL13544010 | 0.87 | CCR5 (0.78) | CCR5OPRM1OPRL1 | |
| SCHEMBL13544009 | 0.86 | CCR5 (0.85) | CCR5OPRM1OPRL1 | |
| SCHEMBL4686334 | 0.84 | CCR5 (0.86) | CCR5OPRM1OPRL1 | |
| SCHEMBL13544014 | 0.83 | CCR5 (0.86) | CCR5OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | claimed |
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | claimed |
| EP-1569933-B1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | CCR5, CCL5, CXCR1 | CCR5 1/4885OPRM1 153/4885OPRL1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.